HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Committee Hearing Shows How Talc/Asbestos Concerns Could Be Impetus For Cosmetics Reform

Executive Summary

“If I were in your shoes or in Commissioner Gottlieb’s shoes I wouldn’t wait another day to require a warning on all [talc-containing cosmetic] products,” EWG’s Scott Faber told a House Oversight and Reform subcommittee March 12, while maintaining that large-scale regulatory changes are what's truly needed to protect users of talcum powders and other personal-care items.

You may also be interested in...



J&J’s Discontinuation Of Johnson’s Baby Powder Linked To April Federal Court Ruling

Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.

FDA To Hold Public Meeting In February on Cosmetic Talc-Asbestos Test Methods

Recommendations from an FDA-led interagency work group regarding methods for detecting and measuring asbestos in talc and talc-containing cosmetics will be presented at the agency’s planned public meeting in Silver Spring, MD, on 4 February. The recommendations are summarized in the FDA's meeting notice, which follows contentious cosmetic product recalls based on asbestos findings.

Cosmetics News In Brief: NY Slaps Limit On Cosmetic 1,4-Dioxane Content; J&J Talc Drama; IFF Merger

Suspected trace carcinogen 1,4-dioxane must be limited to 2 parts per million in personal cleansing products sold in New York after 31 December 2022, and 1 ppm one year later, under recently enacted legislation. More cosmetics news in brief.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel